C-Reactive Protein Testing Market Size, Share, Competitive Landscape and Trend Analysis Report, by Assay Type and Application : Global Opportunity Analysis and Industry Forecast, 2021-2030

C-Reactive Protein Testing Market Insights 2030:

The global c-reactive protein testing market size was valued at $2,765.07 million in 2020, and is estimated to reach $3,568.69 million by 2030, growing at a CAGR of 2.4% from 2021 to 2030. C-reactive protein (CRP) is an acute-phase protein produced by liver, whose concentrations in the blood rises in response to inflammatory disorders. The c-reactive protein (CRP) test determines the amount of CRP in the blood plasma.

Inflammation is the body's response to an injury or infection by protecting tissues. Autoimmune disorders and chronic diseases such as diabetes, cardiovascular diseases, endometriosis, cancer, and rheumatoid arthritis can cause inflammation. CRP protein has the ability to multiply 1,000-fold in areas of infection or inflammation. The test is used to diagnose infections as well as other medical conditions. The test does not identify direct cause of inflammation, but the degree of inflammation caused by other factors. It is an accurate early warning sign of inflammation or an injury.

Growing geriatric population worldwide, as well as escalating demand for healthcare services is expected to drive the market growth. Ageing population is associated with an increase in prevalence of chronic diseases, which is expected lead to an increase in number of tests. Furthermore, sedentary lifestyles and lowered immunity drives CRP testing in healthcare facilities. Diagnostic testing uses increases with age and it is expected that the ageing population would increase demand for c-reactive protein testing. Furthermore, older patients are more likely to have comorbidities such as chronic illnesses, osteoarthritis, and heart problems. As a result, the aforementioned factors are expected to fuel growth of the CRP testing market during the forecast period.

One of the major factors driving the market is the rising prevalence of chronic diseases such as the diabetes, cardiovascular, cancer, inflammatory bowel diseases, arthritis in the general population. Early detection of chronic diseases increases the likelihood of successful treatment. As a result, healthcare providers continually emphasize early diagnosis of clinical disorders rather than spending large sums of money on expensive treatments. Furthermore, increase in various initiatives by governments, non-profit organizations, and key players of the market to create awareness for CRP testing’s plays a pivotal role in by spreading the awareness and thus, further boost the c-reactive protein testing market growth. 

The global increase in health disorders has resulted in increased investment in the healthcare industry, which has resulted in technological advancements for determining the levels of c-reactive protein for various diseases. In addition, availability of various point of care devices, rapid kits have boosted the market growth. Furthermore, it reduces medical professional’s workloads by eliminating specimen collection and inspection requests to central laboratories. Thus, development of such novel test kits is anticipated to provide numerous opportunities for key players of the market to invest and contribute towards the market growth during the forecast period. However, availability of alternative disease testing methods for diseases with higher accuracy such as the electrocardiogram (ECG), echocardiogram (ultrasound) for screening of cardiac diseases, and similar products for other diseasesis expected to restrain the c-reactive protein testing market growth.

Impact Of Covid-19 On C-Reactive Protein Testing Market (Pre And Post Analysis)

The COVID-19 outbreak is anticipated to have a positive impact on the growth of the global c-reactive protein testing market. A huge number of clinics and hospitals across the globe were restructured to increase hospital capacity for patients diagnosed with COVID-19. The lockdown led to disruption of manufacturing and transportation of healthcare essentials. Furthermore, other factors responsible for the impact on the market include limited availability of medical care, shortage of healthcare staff and rise in burden of COVID-19 related hospitalization. 

However, c-reactive protein (CRP) had been identified as an important marker that increases significantly in severe COVID-19 patients. Its concentration decreases as the inflammatory stages end and the patient heals, thus being utilized as a useful marker for monitoring disease severity and lung lesions. Therefore, CRP testing’s increased in the COVID-19 pandemic and led growth of the market significantly.

Furthermore, untapped, emerging markets are expected to offer potential growth opportunities, due to improved healthcare infrastructure, increase in unmet healthcare needs, and rise in R&D activities. In addition, various technological advancements in rapid diagnostic kits is an emerging opportunity for key players to invest in the c-reactive protein testing market.

C-reactive Protein Testing Market Segmentation

The global c-reactive protein testing market is segmented into assay type, application, and region. On the basis of assay type, the market is categorized into enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), immunoturbidimetric assay, and others. 

By application, the market is bifurcated into diabetes, rheumatoid arthritis, cardiovascular disease, inflammatory bowel disease and others. Region wise, the c-reactive protein testing market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Segment review

Depending on the assay type, the immunoturbidimetric assay segment dominated the c-reactive protein testing market in 2020, and is expected to continue this trend during the forecast period, owing to its higher sensitivity, and rapid result technology.

By application, the cardiovascular disease segment exhibited the highest growth in 2020, and is expected to continue this trend during the forecast period, owing to surge in cardiovascular diseases globally

North America accounted for a majority of the global c-reactive protein testing market share in 2020, and is anticipated to remain dominant during the forecast period. This is attributed to increase in prevalence of inflammatory diseases, increase in unhealthy lifestyle, development of new solutions for detection, presence of key players, and rise healthcare expenditure in the region. However, Asia-Pacific is anticipated to witness notable growth, owing to rise in chronic diseases, rise in R&D activities and increase in investments in the healthcare sector in the region. Moreover, India and China are expected to grow at high CAGR in Asia-Pacific c-reactive protein testing market.   

The key players operating in the global c-reactive protein testing market are Abbott Laboratories, Danaher Corporation (Beckman Coulter Inc.), F. Hoffmann-La Roche AG, Horiba, Ltd., Quest Diagnostics Incorporated, Merck KGAA (Millipore Sigma), Randox Laboratories Limited, Laboratory Corporation of America Holdings, Thermo Fisher Scientific, Inc., and Zoetis Inc. (Abaxis Inc.).

Key Benefits For Stakeholders

• The study provides an in-depth analysis of the c-reactive protein testing market, and the current trends and future estimations to elucidate the imminent investment pockets.
• It presents a quantitative analysis of the market from 2021 to 2030 to enable stakeholders to capitalize on the prevailing c-reactive protein testing market opportunities.
• Extensive analysis of the market based on procedures and services assists to understand the trends in the industry.
• Key players and their strategies are thoroughly analyzed to understand the competitive outlook of the c-reactive protein testing market.

  C-Reactive Protein Testing Market Report Highlights

Aspects	Details
By Assay Type	Enzyme-linked immunosorbent assay (ELISA) Chemiluminescence Immunoassay (CLIA) Immunoturbidimetric assays Others
By Application	Diabetes Rheumatoid Arthritis Cardiovascular Disease Inflammatory Bowel Disease Others
By Region	North America  (U.S., Canada, Mexico) Europe  (UK, Germany, France, Spain, Italy, Rest of Europe) Asia-Pacific  (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific) LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players	Zoetis Inc. (Abaxis Inc.), Danaher Corporation (Beckman Coulter Inc.), Abbott Laboratories, Merck KGAA (Millipore Sigma), Horiba, Ltd., Quest Diagnostics Incorporated, Randox Laboratories Limited, Laboratory Corporation of America Holdings, F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Inc.

Analyst Review

This section provides opinions of top level CXOs in the global c-reactive protein testing market. According to the insights of CXOs, c-reactive protein testing measures the level on CRP in the blood. CRP is a protein that is produced by liver and its level increases in response to inflammation caused due to infection or an injury. CRP testing is done with the help of various assays such as enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), and immunoturbidimetric assays.

As per CXOs, escalating number of individuals suffering from chronic diseases and rise in inflammatory disorders are the major factor that drive growth of the global reactive protein testing market. Furthermore, this rise of diseases is estimated to surge the sheer volume of testing and is expected to have a significant impact on growth of the market during the forecast period. The market gains interest of healthcare companies, owing to surge in R&D and increase in focus in adoption of c-reactive protein testing for safe and effective application.

North America is expected to witness highest growth, in terms of revenue, owing to rise in chronic disease, availability of sophisticated healthcare infrastructure for testing, robust R&D infrastructure for life science researches, presence of key players, and advancements in healthcare investments. Asia-Pacific is expected to register the fastest CAGR during the forecast period, owing rapidly growing geriatric population, increase in public–private investments, continuous government support for pharmaceutical and biotechnology R&D, and rise in initiatives toward health awareness and early diagnosis of disease.

Author Name(s) : Shraddha Mali| Madhuvanti Divekar | Roshan Deshmukh

Related Tags

• Immunology And Serology
• Diabetes
• Oncology
• Molecular Biology
• Nsaid

^*Terms and Conditions Apply